Hyman Phelps and McNamara
Firm Publications

Proposed Legislation Would Create a New Conditional Approval Pathway to Market for Regenerative Medicine Products
March 31 2016

In the emerging world of regenerative medicine, there is a stark dichotomy in the level of regulation applied to products derived from human cells and tissues, or what FDA calls “human cells, tissue or cellular and tissue?based products” (HCT/Ps).

Click here to view the full article

If you have any questions regarding the above information, please contact:
Jeffrey K. Shapiro (202) 737-9633 jshapiro@hpm.com